Systemic therapy for advanced hepatocellular carcinoma: past, present, and future

Area of Science:

• Hepatocellular Carcinoma Research
• Oncology Therapeutics
• Molecular Pathway Elucidation

Background:

• Hepatocellular carcinoma (HCC) incidence is rising in Western countries, largely due to hepatitis C.
• HCC presents significant therapeutic challenges, including chemoresistance, liver dysfunction, advanced stage at diagnosis, and difficulty in assessing treatment response.
• Traditional chemotherapy offers limited survival benefits for HCC patients.

Purpose of the Study:

• To review published clinical trials on systemic therapy and immunotherapy for hepatocellular carcinoma.
• To assess the impact of current and emerging treatments on HCC management.

Main Methods:

• Systematic review of clinical trial results.
• Analysis of systemic therapy and immunotherapy data for HCC treatment.

Main Results:

• Targeted agents, informed by molecular pathway research, demonstrate potential.
• Sorafenib, a multikinase inhibitor, has shown survival benefits in advanced HCC patients with preserved liver function.
• Other agents like sunitinib, bevacizumab, EGFR inhibitors, and mTOR inhibitors show activity in smaller studies, while immunotherapy offers potential for cancer regression.

Conclusions:

• Emerging targeted therapies and immunotherapies represent promising advancements.
• These new agents offer diverse mechanisms of action for treating advanced HCC.
• Novel therapeutic strategies are expanding options for patients with advanced liver cancer.